Chester County News and Community Website
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported second quarter 2025 financial results and outlined key milestones in its effort to bring INO-3107, a DNA medicine candidate for recurrent respiratory …
INOVIO Advances Toward FDA Filing for INO-3107 as Quarterly Losses Narrow Read More
YARDLEY, PA — Smart Sand, Inc. (NASDAQ: SND) reported a sharp increase in sales volumes and revenues for the second quarter of 2025, though higher logistics costs and negative cash …
Smart Sand Posts Strong Sales Growth Despite Cash Flow Pressures in Second Quarter Read More
EXTON, PA — Innovative Solutions & Support, Inc. (Nasdaq: ISSC) posted strong fiscal third quarter 2025 results, driven by contributions from its newly acquired F-16 product line and progress on …
Innovative Solutions & Support Doubles Revenue in Q3, Expands Capacity and Financing for Growth Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported second-quarter 2025 financial results and outlined key regulatory and business milestones, including plans to resubmit its Biologics License Application (BLA) for MOLBREEVI, …
Savara to Resubmit BLA for Rare Lung Disease Treatment as Losses Widen in Q2 Read More
WILMINGTON, DE — Onfolio Holdings Inc. (NASDAQ: ONFO, ONFOW; OTC: ONFOP) announced its financial results for the second quarter of fiscal 2025, reporting significant revenue and profit growth alongside a …
Onfolio Reports Strong Revenue Growth, Narrowed Losses in Second Quarter Read More NORTH WALES, PA — Toppoint Holdings Inc. (NYSE American: TOPP) reported second-quarter 2025 revenue of $3.97 million, down from $4.70 million a year earlier, as declines in waste paper and …
Toppoint Holdings Sees Metals Growth Amid Softer Waste Paper and Import Volumes Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has shifted its strategic focus toward its oral SMARCA2 degrader, PRT7732, while reporting narrower second-quarter losses and steady progress across its oncology …
Prelude Therapeutics Refocuses SMARCA2 Program, Cuts Quarterly Losses Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) posted second-quarter 2025 results and outlined strategic progress on its antiviral drug pipeline, with a focus on COVID-19 and influenza treatments designed …
Traws Pharma Reports Q2 Results, Advances COVID-19 and Influenza Antiviral Programs Read More
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported second-quarter 2025 results, highlighting progress toward a planned Biologics License Application (BLA) for nomlabofusp, a potential first disease-modifying therapy for …
Larimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA Filing Read More
HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is betting on newly expanded reimbursement codes and emerging treatment applications for its XTRAC excimer laser to drive long-term growth, even …
STRATA Skin Sciences Eyes Growth from Expanded Reimbursement Despite Q2 Revenue Decline Read More